Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Hilary Duff's husband responds to Ashley Tisdale's 'toxic' mom group claims: The drama, explained - 2Turkey key underlying issue as Israel, Greece, Cyprus hold summit
- 3Figure out How to Alter Your Volvo XC40 for Further developed Solace
- 4Vote in favor of the bloom plan that adds a bit of excellence to your life!
- 5Instructions to Redo Your Kona SUV for Improved Tasteful Allure and Usefulness
- Guaranteeing Quality Medical care with Federal medical care Benefit Plans.
- Astronomers may have spotted the 1st known 'superkilonova' double star explosion
- Israel’s mixed messaging on Christmas draws controversy
- All that You Really want to Be familiar with Dental Inserts Facilities
- Doctors say changes to US vaccine recommendations are confusing parents and could harm kids
- Which Film Has the Incomparable Melodic Score?
- Born under fire: MDA delivers baby in Jerusalem minutes before rushing to shelter
- Jamie Dimon warns Iran war could drive inflation, interest rates higher
- Haunting Giant Squid Surfaces in Japan and Devours Its Prey (Video)
